Todd Douglas

Todd Douglas

Auto-generated profile, based on publicly available information

Todd Douglas

Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Immunity
Verified
Journal Article
Closed access
JDJeremy Dupaul-Chicoine
Jeremy Dupaul-Chicoine
AAAzadeh Arabzadeh
Azadeh Arabzadeh
MDMaryse Dagenais
Maryse Dagenais
TDTodd Douglas
Todd Douglas
CCClaudia Champagne
Claudia Champagne
MSMaya Saleh
Maya Saleh

1 December 2014 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
FBFrançois Barbé
François Barbé
TDTodd Douglas
Todd Douglas
MSMaya Saleh
Maya Saleh

1 September 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TDTodd Douglas
Todd Douglas
CCClaudia Champagne
Claudia Champagne
AMAlexandre Morizot
Alexandre Morizot
JLJean-Martin Lapointe
Jean-Martin Lapointe
MSMaya Saleh
Maya Saleh
Chronic proliferative dermatitis in mice (cpdm) is a spontaneous multiorgan inflammatory disorder with pathological hallmarks similar to atopic dermatitis and psoriasis in humans. Cpdm mice lack expression of SHANK-associated RH domain–interacting protein, an adaptor of the linear ubiquitin assembly complex, which acts in the NF-κB pathway to promote inflammation and protect from apoptosis and necroptosis. Although skin inflammation in cpdm mice is driven by TNF- and RIPK1-induced cell death, the contribution of initiating innate immunity sensors and additional inflammatory pathways remains poorly characterized. In this article, we show that inflammasome signaling, including the expression and activation of the inflammatory caspase-1 and -11 and IL-1 family cytokines, was highly upregulated in the skin of cpdm mice prior to overt disease onset. Genetic ablation of caspase-1 and -11 from cpdm mice significantly reduced skin inflammation and delayed disease onset, whereas systemic immunological disease persisted. Loss of Nlrp3 also attenuated skin disease, albeit more variably. Strikingly, induction of apoptosis and necroptosis effectors was sharply decreased in the absence of caspase-1 and -11. These results position the inflammasome as an important initiating signal in skin disease pathogenesis and provide novel insights about inflammasome and cell death effector cross-talk in the context of inflammatory diseases.

4 March 2017 in OncoImmunology
Verified
Journal Article
Closed access
MDMaryse Dagenais
Maryse Dagenais
JDJeremy Dupaul-Chicoine
Jeremy Dupaul-Chicoine
TDTodd Douglas
Todd Douglas
CCClaudia Champagne
Claudia Champagne
AMAlexandre Morizot
Alexandre Morizot
MSMaya Saleh
Maya Saleh
Breast cancer is the most common cancer in women and the second leading cause of female cancer-related death worldwide. Inflammation is an established hallmark of tumorigenesis and an important determinant of tumor outcome and response to therapy. With advances in cancer immunotherapy, there is an urgent need to dissect the contribution of specific immune effectors in cancer development. Here, we genetically investigated the role of the Interleukin-1 (IL-1) receptor 1 (IL-1R1) pathway in breast cancer tumorigenesis and metastasis using the MMTV-PyMT mouse model. Our results indicate that IL-1R1 signaling suppresses mammary tumor cell proliferation early in tumorigenesis and curbs breast cancer outgrowth and pulmonary metastasis. We show that PyMT/Il1r1−/− mice had a higher primary tumor burden and increased mortality rate compared to IL-1R1-sufficient PyMT control mice. This phenotype was independent of the inflammatory caspases-1/-11 but driven by IL-1α, as PyMT/Il1a−/− mice phenocopied PyMT/Il1r1−/− mice. Collectively, our results suggest that IL-1α-mediated IL-1R1 signaling is tumor-suppressive in PyMT-driven breast cancer.

1 December 2019 in Cell Reports
Verified
Journal Article
Open access
TDTodd Douglas
Todd Douglas
MSMaya Saleh
Maya Saleh
Linear ubiquitination has emerged as an important post-translational modification that regulates NF-κB activation, inflammation, and cell death in both immune and non-immune compartments, including the skin. The deubiquitinase OTULIN specifically disassembles linear ubiquitin chains generated by the linear ubiquitin assembly complex (LUBAC) and is necessary to prevent embryonic lethality and autoinflammatory disease. Here, we dissect the direct role of OTULIN in cell death and find that OTULIN limits apoptosis and necroptosis in keratinocytes. During apoptosis, OTULIN is cleaved by capase-3 at Asp-31 into a C-terminal fragment that restricts caspase activation and cell death. During necroptosis, OTULIN is hyper-phosphorylated at Tyr-56, which modulates RIPK1 ubiquitin dynamics and promotes cell death. OTULIN Tyr-56 phosphorylation is counteracted by the activity of dual-specificity phosphatase 14 (DUSP14), which we identify as an OTULIN phosphatase that limits necroptosis. Our data provide evidence of dynamic post-translational modifications of OTULIN and highlight their importance in cell death outcome.

1 November 2014 in Current Opinion in Gastroenterology
Verified
Journal Article
Closed access
MDMaryse Dagenais
Maryse Dagenais
TDTodd Douglas
Todd Douglas
MSMaya Saleh
Maya Saleh
To critically review recent advances on the role of programmed necrosis and other cell death modalities in intestinal health and inflammatory bowel disease. Tight regulation of intestinal epithelial cell proliferation and cell death is required for intestinal physiology, and to maintain an integral barrier that restricts microbiota translocation and ensures immune tolerance. Apoptosis has long been considered as a normal part of intestinal epithelial cell turnover. However, recent studies have demonstrated that excessive cell death leads to deleterious intestinal inflammation, as is observed in inflammatory bowel disease. Additionally, a novel form of cell death dubbed programmed necrosis, or necroptosis, has been recently shown to be pathological in the gut. The role of cell death in the intestine is complex and its potential implication in intestinal diseases, and inflammatory bowel disease in particular, needs to be reevaluated.